Disorders of Solute Carrier (SLC) Transporters: A Clinical Review for the Internist

Review Article | Internal Medicine

Dr Neeraj Manikath , claude.ai

Abstract

Solute carrier (SLC) transporters comprise the largest superfamily of membrane transport proteins in the human genome, encompassing over 400 members organized into 65 families. These proteins mediate the transmembrane movement of sugars, amino acids, ions, neurotransmitters, and nucleotides across epithelial and neuronal membranes. Mutations in SLC genes underlie a heterogeneous group of rare but clinically important disorders that frequently present to the general internist in disguise — masquerading as epilepsy, intellectual disability, metabolic syndrome, pulmonary disease, or unexplained electrolyte derangements. This review synthesizes contemporary knowledge on five paradigmatic SLC disorders with an emphasis on clinical recognition, bedside diagnostic nuance, and practical management hacks relevant to the postgraduate physician and consultant internist.

Keywords: SLC transporters, GLUT1 deficiency, SGLT2, creatine transporter deficiency, lysinuric protein intolerance, Gitelman syndrome, Bartter syndrome

Introduction

The SLC superfamily encodes facilitated transporters, cotransporters, and exchangers that are indispensable to normal physiology. From the renal tubule to the blood-brain barrier, from the intestinal enterocyte to the skeletal muscle membrane, SLC proteins constitute the molecular machinery through which nutrients and ions traverse biological membranes. Their functional importance is underscored by the growing catalogue of human diseases attributable to their dysfunction — the "SLC channelopathies" of metabolic medicine.

Despite their frequency in specialist genetics clinics, SLC disorders reach the internist through unexpected portals: the young adult with unexplained movement disorder, the asymptomatic glycosuric patient erroneously labeled diabetic, the boy with intellectual disability and absent speech, or the middle-aged patient with unexplained pulmonary alveolar proteinosis. Recognizing these presentations requires a clinician who can synthesize biochemistry, genetics, and clinical medicine at the bedside.

This review is organized around five illustrative SLC disorders, each chosen to represent a distinct clinical lesson. The discussion integrates the latest genotype-phenotype data, diagnostic algorithms, and management principles.

SLC2A1 (GLUT1) Deficiency: The Adult-Onset Paroxysmal Exercise-Induced Dyskinesia

Background and Molecular Basis

GLUT1 deficiency syndrome (GLUT1-DS), caused by heterozygous loss-of-function mutations in SLC2A1, was first described in 1991 by De Vivo et al. as a cause of infantile epilepsy and developmental delay. However, the phenotypic spectrum extends well beyond the classic triad of epilepsy, acquired microcephaly, and movement disorder. A particularly important and underrecognized adult phenotype is paroxysmal exercise-induced dyskinesia (PED) — involuntary dystonic or choreoathetotic movements precipitated by physical exertion, typically affecting the lower limbs.

GLUT1 is the principal glucose transporter at the blood-brain barrier. Deficiency results in cerebral glucose hypometabolism disproportionate to systemic hypoglycemia. Exercise presumably worsens cerebral glucose deficiency by shunting lactate and pyruvate peripherally while simultaneously increasing neuronal glucose demand — a mechanism that explains why carbohydrate ingestion aborts attacks.

The Clinical Fingerprint

The adult with GLUT1-DS presenting with PED is one of the most satisfying diagnoses in neurology-internal medicine interface practice. Key clinical clues include:

Attacks lasting 5–30 minutes following sustained exercise (e.g., walking, cycling), with choreiform or dystonic movements predominantly in the legs
Pre-attack hunger or fatigue — patients often learn empirically that eating before exercise prevents attacks
Absence of ictal EEG changes during attacks (distinguishing PED from focal motor seizures)
Family history consistent with autosomal dominant inheritance, though de novo mutations account for ~10% of cases
Low to low-normal fasting CSF glucose with a CSF:plasma glucose ratio <0.45 (normal >0.60); this is the diagnostic cornerstone
Normal serum glucose at all times — a frequent source of diagnostic confusion

A critically important pearl: the absence of epilepsy does not exclude GLUT1-DS. The adult PED phenotype may exist in isolation, and these patients are systematically missed because they are evaluated by neurologists who do not perform lumbar puncture for movement disorders, or by internists who do not consider neurometabolic disease.

🔑 Diagnostic Pearl: Always measure CSF glucose simultaneously with serum glucose. A ratio <0.45 is highly suggestive; <0.35 is virtually diagnostic. Perform the LP after a 4-hour fast. Note that prior glucose infusion or a recent meal can falsely normalize the ratio.

🦪 Oyster: GLUT1-DS may present as paroxysmal kinesigenic or non-kinesigenic dyskinesia, absence epilepsy with carbohydrate-responsive attenuation of spikes, or even as alternating hemiplegia of childhood. Erythrocyte GLUT1 uptake assay (3-O-methyl-D-glucose uptake) and SLC2A1 sequencing confirm the diagnosis when CSF studies are borderline.

Management Hacks

The ketogenic diet remains the cornerstone of treatment, exploiting the fact that ketone bodies — transported by MCT1/MCT2, not GLUT1 — can substitute as cerebral fuel. In adults, the modified Atkins diet (MAD) and low-glycemic index treatment (LGIT) offer more palatable alternatives with comparable efficacy for movement disorder control.

Clinician hack: Advise patients to consume a carbohydrate-rich snack 20–30 minutes before exercise. This is a low-cost, immediately implementable intervention while awaiting formal dietary consultation. Avoid prolonged fasting, alcohol (which inhibits gluconeogenesis), and valproate (which inhibits fatty acid oxidation and can worsen the phenotype). Caffeine, phenobarbital, and methylxanthines are all contraindicated as they inhibit GLUT1 transport directly.

SLC5A2 (SGLT2) Mutations: Familial Renal Glucosuria and the Hypoglycemia Paradox

Background

Sodium-glucose cotransporter-2 (SGLT2), encoded by SLC5A2, mediates approximately 90% of glucose reabsorption in the proximal convoluted tubule (S1 and S2 segments). Biallelic loss-of-function mutations cause familial renal glucosuria (FRG), a benign condition characterized by persistent glucosuria despite normoglycemia. Heterozygous carriers exhibit a partial phenotype (type A FRG with reduced reabsorptive capacity, type B with reduced threshold only).

The pharmacological irony of the SGLT2 inhibitor drug class — now foundational to treatment of type 2 diabetes, heart failure, and CKD — is that its clinical rationale derives directly from the phenotypic characterization of FRG patients: decades of follow-up have demonstrated that individuals with complete SGLT2 deficiency are remarkably healthy, suffering no adverse metabolic consequences from urinary glucose losses of 10–170 g/day.

The Hypoglycemia Paradox

The counterintuitive clinical scenario arises when FRG patients are inadvertently worked up for hypoglycemia. Consider: a patient presents with dipstick-positive glucosuria during a routine medical examination. Standard reflex testing — an OGTT or HbA1c — returns normal. The urine glucose persists. If the clinician then checks a finger-prick glucose while the patient is symptomatic with tremulousness or diaphoresis, the reading may be genuinely low — but not due to SGLT2 deficiency per se.

The paradox unfolds as follows: SGLT2-null individuals who are also on a caloric-restrictive diet, or who have concurrent type 1 diabetes or insulinoma, may exhibit exaggerated hypoglycemia because their inability to reabsorb filtered glucose amplifies urinary losses, exacerbating glucose deficit states. Furthermore, the SGLT2i drug class causes euglycemic diabetic ketoacidosis (euDKA) — a diagnosis that is frequently missed because the serum glucose is normal or mildly elevated while the anion gap is widening insidiously.

🔑 Diagnostic Pearl — The FRG Workup Ladder:

Confirm persistently positive dipstick urine glucose on fasting morning sample

Perform simultaneous urine and plasma glucose (calculate fractional excretion of glucose: FEG = [urine glucose × plasma creatinine] / [plasma glucose × urine creatinine]; FEG >0.2% is abnormal)

OGTT to exclude diabetes mellitus

Genetic testing (SLC5A2 sequencing and deletion/duplication analysis)

If FRG confirmed — reassure and discharge. No dietary restriction necessary. Annual surveillance for glycemic status given marginally increased lifetime DM2 risk.

🦪 Oyster: Up to 6% of individuals with FRG harbor co-existing mutations in SLC5A1 (SGLT1, expressed in intestine and S3 segment) or HNF1A (MODY3, which causes renal tubular dysfunction). Always exclude MODY in a young, non-obese glucosuric patient before assuming benign FRG, particularly if there is a strong family history of diabetes.

Management and the euDKA Trap

For patients prescribed SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin), internists must recognize euDKA as a genuine emergency. The clinical footprint is subtle: patient on an SGLT2i presents with nausea, vomiting, and malaise; glucose is 11–14 mmol/L (200–250 mg/dL); anion gap is 18–24; beta-hydroxybutyrate is markedly elevated.

The hack: Order beta-hydroxybutyrate in any SGLT2i-treated patient with an unexplained anion gap or who presents perioperatively. The STOP-euDKA rule — cease the drug 3–4 days before elective surgery, ensure adequate carbohydrate intake — is underused in surgical admissions.

SLC6A8 (Creatine Transporter) Deficiency: The X-Linked Intellectual Disability with Seizures

Background

SLC6A8 encodes the creatine transporter (CRT1), responsible for cellular uptake of creatine in brain, muscle, and other tissues. X-linked creatine transporter deficiency (CTD) is caused by hemizygous mutations in males and (less severely, due to X-inactivation skewing) heterozygous mutations in females. It constitutes the most common of the three cerebral creatine deficiency syndromes (CCDS), which also include guanidinoacetate methyltransferase (GAMT) deficiency and arginine:glycine amidinotransferase (AGAT) deficiency — the latter two being autosomal recessive and creatine-supplementation responsive.

CTD is characterized by:

Intellectual disability, often moderate-to-severe in males
Language delay disproportionately affecting expressive speech
Behavioral abnormalities — autism spectrum features, hyperactivity, self-injurious behavior
Epilepsy — in 50–70% of affected males; typically resistant to standard anticonvulsants

The estimated prevalence among males with unexplained intellectual disability is 1–2%, making it clinically significant and systematically underdiagnosed.

Bedside and Biochemical Recognition

CTD should enter the differential diagnosis of any male with moderate intellectual disability + seizures + absent or severely limited speech. The absence of dysmorphic features (unlike chromosomal syndromes) is characteristic. Some affected boys have macrocephaly.

The biochemical hallmark is the urinary creatine:creatinine ratio. In affected males, this ratio is elevated (typically >1.5, normal <0.2 in adults), reflecting failure of cellular creatine uptake and consequent urinary spillover of absorbed dietary creatine. This is a robust, inexpensive, first-line screen.

🔑 Diagnostic Pearl: MR spectroscopy of the brain demonstrating absent or markedly reduced creatine peak in the brain is virtually pathognomonic of CTD (and CCDS in general). The creatine peak at 3.03 ppm is one of the most stable signals in MRS. Its absence in a child with intellectual disability is a definitive clue.

🦪 Oyster: Females carrying SLC6A8 mutations exhibit a bimodal phenotype: mildly or severely affected depending on the degree of skewed X-inactivation. A carrier mother of an affected boy may herself have mild learning difficulties, mood dysregulation, or seizures. Testing of maternal creatine:creatinine ratio and SLC6A8 sequencing is essential for genetic counseling.

Distinguishing CTD from GAMT and AGAT deficiency is clinically critical, because GAMT and AGAT deficiencies respond to creatine monohydrate supplementation, whereas CTD does not respond to oral creatine (the transporter is absent, so creatine cannot enter cells). This distinction can be life-altering for families.

Feature	AGAT Deficiency	GAMT Deficiency	CTD
Inheritance	AR	AR	X-linked
Urine creatine	Low	Low/Normal	High
Urine GAA	Low	High	Normal
Plasma creatine	Low	Variable	Variable
Responds to creatine Rx	Yes	Partially	No
Brain MRS	Low Cr	Low Cr	Low Cr

Management Hacks

For CTD, the objective is to maximize available creatine transport via residual transporter function if a partial defect exists. While oral creatine supplementation alone is ineffective, combination strategies under investigation include:

Creatine + cyclocreatine (analogue transported independently)
High-dose L-arginine to upregulate residual SLC6A8 expression
Dietary management to optimize precursor availability

For the practicing internist, the most important action is timely diagnosis to avoid years of futile anticonvulsant escalation and to offer accurate genetic counseling. Referral to a metabolic neurology center is appropriate once CTD is confirmed.

SLC7A7 (Lysinuric Protein Intolerance): The Multisystem Disease with Pulmonary Alveolar Proteinosis

Background

Lysinuric protein intolerance (LPI) is caused by biallelic loss-of-function mutations in SLC7A7, encoding the y+LAT1 subunit of the cationic amino acid transporter. This transporter mediates the efflux of lysine, arginine, and ornithine across the basolateral membrane of intestinal epithelial cells and the apical membrane of renal proximal tubule cells. Loss of function results in impaired absorption of these dibasic amino acids, with consequent urea cycle dysfunction, hyperammonemia, and deficiency of arginine and lysine.

LPI is most prevalent in Finland (1:60,000), Japan, and among Italian families from southern Italy. However, it occurs globally and should be considered irrespective of ethnicity.

The Multisystem Clinical Phenotype — A Diagnostic Minefield

LPI is one of internal medicine's most multifaceted rare diseases, routinely challenging diagnosticians across hepatology, pulmonology, nephrology, immunology, and hematology:

1. Gastrointestinal: Protein aversion from childhood (patients instinctively avoid meat and dairy), postprandial vomiting, hepatosplenomegaly, and failure to thrive. Adults may have cirrhosis.

2. Hematological: Anemia, thrombocytopenia, leukopenia — often misattributed to liver disease. Hemophagocytic lymphohistiocytosis (HLH) is a dreaded and potentially fatal complication, occurring in ~10% of LPI patients, typically triggered by infection. The LPI-HLH association is frequently missed because the treating intensivist does not think of an aminoacidopathy as a precipitant.

3. Renal: Tubulointerstitial nephritis and progressive CKD. Membranoproliferative glomerulonephritis has been described.

4. Immunological: Recurrent infections, systemic lupus erythematosus-like autoimmune disease, anti-dsDNA antibodies. The mechanistic link is thought to involve arginine depletion impairing nitric oxide synthesis and immune effector function.

5. Pulmonary — The Devastating Complication: Pulmonary alveolar proteinosis (PAP) occurs in 15–20% of LPI patients and may be the presenting feature in adults. LPI-PAP results from arginine deficiency impairing macrophage function (specifically GM-CSF signaling), leading to alveolar surfactant accumulation. The chest CT appearance — "crazy paving pattern" with ground-glass opacities and septal thickening — is identical to autoimmune PAP.

🔑 Diagnostic Pearl: Any patient with PAP, especially if young or with a family history, should have plasma amino acid chromatography performed. The biochemical fingerprint of LPI is pathognomonic: markedly elevated plasma glutamine and alanine (reflecting transamination to bypass the urea cycle block) with low plasma lysine, arginine, and ornithine. Urinary amino acids show elevated dibasic amino acids (urine lysine, arginine, ornithine). Plasma ammonia may be elevated postprandially even if fasting levels are normal.

🦪 Oyster: In LPI patients presenting with acute hyperammonemic encephalopathy, the trigger is often high protein intake (a meal, TPN, or intercurrent infection with catabolism). Unlike classic urea cycle disorders, LPI patients typically tolerate modest dietary protein because some urea cycle function is preserved; they decompensate at higher loads. Emergency management is identical to other urea cycle disorders: protein restriction, IV dextrose to suppress catabolism, sodium benzoate and phenylbutyrate as nitrogen scavengers, and arginine/citrulline supplementation to replenish urea cycle intermediates.

Hack for the Pulmonologist-Internist: When whole lung lavage is performed for PAP, send lavage fluid for amino acid analysis. LPI-associated PAP lavage fluid shows characteristic proteomic differences from autoimmune PAP. Anti-GM-CSF antibodies are negative in LPI-PAP (positive in autoimmune PAP) — this distinction guides treatment, as rituximab may help autoimmune PAP but LPI-PAP requires citrulline supplementation and protein restriction as the metabolic foundation.

Monitoring Framework in Established LPI

Plasma amino acids (quarterly), LFTs, CBC, renal function
Annual pulmonary function tests and HRCT chest from diagnosis
Ferritin (HLH screen) at each visit and with any febrile illness
Avoid high-protein loads; citrulline supplementation (200–800 mg/kg/day in children, titrated by plasma arginine) is the mainstay

SLC12A3 (Gitelman) and SLC12A1 (Bartter) Genotype-Phenotype Correlations

Molecular Taxonomy

Gitelman syndrome (GS) and Bartter syndrome (BS) are the two cardinal renal tubular hypokalemic alkaloses. They are frequently conflated in clinical practice, yet they differ substantively in their molecular basis, clinical severity, management, and complications.

Gitelman syndrome results from biallelic loss-of-function mutations in SLC12A3, encoding the thiazide-sensitive NaCl cotransporter (NCC) expressed in the distal convoluted tubule (DCT). It is the most common inherited salt-losing tubulopathy, with a heterozygote frequency of ~1%.

Bartter syndrome encompasses five genetically distinct subtypes resulting from defects in genes encoding proteins of the thick ascending limb (TAL) of the loop of Henle:

Type I (BS-I): SLC12A1 — NKCC2 cotransporter
Type II (BS-II): KCNJ1 — ROMK potassium channel
Type III (BS-III): CLCNKB — chloride channel ClC-Kb (also called "classic Bartter")
Type IV (BS-IV): BSND or digenic CLCNKA/CLCNKB — Barttin or dual chloride channel defect, associated with sensorineural deafness
Type V (BS-V): CASR gain-of-function — constitutively active calcium-sensing receptor

The Bedside Differential: Gitelman vs. Bartter

The clinician's most practical challenge is distinguishing GS from BS, particularly BS-III (which can mimic GS phenotypically). The following framework applies:

Feature	Gitelman (SLC12A3)	Bartter (esp. SLC12A1)
Age of presentation	Adolescence/adulthood	Infancy/childhood
Prenatal history	Normal	Polyhydramnios
Serum magnesium	Low (hypomagnesemia in >90%)	Normal
Serum calcium	Low-normal (hypocalciuria)	Normal/elevated (hypercalciuria → nephrocalcinosis)
Urine calcium	Low (FECa <0.2%)	High
Renin/aldosterone	Elevated	Elevated
PGE2	Normal	Elevated (especially neonatal BS)
Indomethacin response	Poor	Good (especially BS-I/II)
Sensorineural deafness	Absent	Present in BS-IV only
Severity	Mild-moderate	Moderate-severe (BS-I/II)

🔑 Diagnostic Pearl — The Urine Calcium Trick: Urine calcium-to-creatinine ratio (spot) or 24-hour urine calcium is the single most discriminating bedside test. Gitelman causes hypocalciuria (FECa <0.2%, urine Ca:Cr <0.1) due to upregulation of the DCT calcium channel TRPV5. Bartter types I, II, and IV cause hypercalciuria and nephrocalcinosis. BS-III may show normal or low urine calcium, contributing to diagnostic overlap with GS.

🦪 Oyster: CLCNKB mutations (BS-III) produce the widest phenotypic range of any Bartter subtype — from a neonatal presentation indistinguishable from antenatal BS-I/II, through a classic school-age presentation, to a Gitelman-like adult phenotype with hypomagnesemia and hypocalciuria. This genotype-phenotype dissociation means that BS-III patients may have been incorrectly diagnosed with GS for years. Molecular genetic testing is essential when the phenotype is atypical.

Genotype-Specific Management Hacks

Gitelman syndrome:

Oral magnesium supplementation is mandatory (magnesium oxide or magnesium glycinate — the latter has better GI tolerability). Target serum Mg >0.6 mmol/L.
Potassium repletion: oral KCl supplementation; amiloride (a potassium-sparing diuretic that acts distally) is preferred over spironolactone because it is not aldosterone-dependent and has better evidence in GS.
NSAIDs: generally not indicated in GS (unlike BS).
GS in pregnancy is a high-risk scenario: hypomagnesemia worsens uterine contraction disorders; pre-eclampsia risk is debated but IV magnesium infusions may be required. Neonatal hypokalemia in the offspring has been reported.

Bartter syndrome (SLC12A1 and others):

Indomethacin 1.5–3 mg/kg/day (in neonatal and infantile BS) suppresses the prostaglandin-mediated tubular dysfunction and is dramatically effective, particularly in BS-I and BS-II. In adults, indomethacin use requires renal function monitoring.
Amiloride or spironolactone for hypokalemia; ACEI/ARB may reduce hyperaldosteronism.
Nephrocalcinosis surveillance (annual renal ultrasound) is mandatory in BS-I, II, IV.
For BS-IV (deafness subtype), hearing aids and cochlear implant candidacy assessment are integral to multidisciplinary care.

Pitfall alert: Both GS and BS are activated by loop diuretics or thiazides in clinical practice, complicating diagnosis when these drugs have been prescribed empirically for "refractory hypokalemia." A urine chloride >20 mEq/L in the setting of hypokalemic metabolic alkalosis with low BP or normal BP argues for a tubular cause; a urine chloride <10 suggests extra-renal losses (vomiting, laxatives). Covert vomiting (bulimia) must be explicitly excluded in all young females presenting with this biochemical profile.

💡 Practical Hack: The "chloride shunt" assessment is clinically underused. In a patient with suspected GS/BS: obtain urine chloride, urine potassium, and urine sodium from a spot sample. Urine K:Cr ratio >2.5 (mmol/mmol) confirms renal potassium wasting. Urine Cl >40 mmol/L in the absence of diuretic use strongly suggests an SLC12 tubulopathy rather than extra-renal alkalosis.

Cross-Cutting Themes and Clinical Synthesis

Several overarching principles emerge from examining these five disorders:

1. The "normal glucose, abnormal urine" paradox operates in both GLUT1-DS (normal blood glucose despite cerebral insufficiency) and SGLT2 mutations (normal blood glucose despite glucosuria). The internist must divorce the concept of glycemia from glucose transport adequacy.

2. Phenotypic expansion with age is universal in SLC disorders. GLUT1-DS presents differently in infancy (epilepsy), childhood (movement disorder), and adulthood (isolated PED). CTD may be missed in females. LPI-PAP emerges in adulthood despite infantile-onset disease. Genetic diagnoses should not be dismissed merely because the textbook phenotype hasn't manifested.

3. Amino acid chromatography is underordered. In clinical practice, plasma amino acid profiles (particularly for dibasic amino acids, glutamine/alanine elevation) are diagnostic in LPI and would correctly direct the workup in CTD (creatine precursors). Requesting "metabolic screen" on a patient with unexplained multisystem disease is one of the highest-yield investigations in internal medicine.

4. Genetic testing has reshaped clinical diagnosis in the SLC channelopathies. Next-generation sequencing panels for tubulopathies (including SLC12A1, SLC12A3, CLCNKB, KCNJ1, BSND, and CASR) are now available in most tertiary centers and should be used early rather than as a last resort.

5. Drug-gene interactions matter. SGLT2 inhibitors are pharmacological mimics of SLC5A2 deficiency and carry the euDKA risk. Valproate and methylxanthines impair GLUT1 function. Aminoglycosides activate CASR (mimicking BS-V). The internist prescribing these drugs to patients with underlying SLC variants must exercise particular vigilance.

Conclusion

Disorders of solute carrier transporters represent a clinically accessible, intellectually rich frontier in adult internal medicine. With the expansion of next-generation sequencing and the growing recognition that "adult-onset" presentations of genetic metabolic disease are not rare exceptions but expected phenotypic variants, the internist is increasingly positioned at the diagnostic frontier. A thorough understanding of the molecular physiology, biochemical screening tests, and clinical pearls outlined here equips the clinician to identify these disorders earlier, avoid diagnostic misattribution, and connect patients with life-altering management.

The cardinal message is one of metabolic vigilance: when a clinical presentation is unexplained by common disease, and particularly when biochemical abnormalities involve glucose, amino acids, or electrolytes in patterns inconsistent with organ failure or medication effect, the SLC transporter disorders deserve systematic consideration.

Key References

De Vivo DC, Trifiletti RR, Jacobson RI, et al. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med. 1991;325(10):703–709.
Leen WG, Klepper J, Verbeek MM, et al. Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain. 2010;133(Pt 3):655–670.
Calado J, Soto K, Clemente C, et al. Novel compound heterozygous mutations in SLC5A2 are responsible for autosomal recessive renal glucosuria. Hum Genet. 2004;114(3):314–316.
Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8(8):495–502.
Bonnet CS, Bhatt DL, Creager MA, et al. SGLT2 inhibitor-associated euglycemic diabetic ketoacidosis. Circulation. 2020;141(20):1622–1624.
Salomons GS, van Dooren SJ, Verhoeven NM, et al. X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-deficiency syndrome. Am J Hum Genet. 2001;68(6):1497–1500.
van de Kamp JM, Mancini GM, Salomons GS. X-linked creatine transporter deficiency: clinical aspects and pathophysiology. J Inherit Metab Dis. 2014;37(5):715–733.
Perheentupa J, Visakorpi JK. Protein intolerance with deficient transport of basic amino acids. Lancet. 1965;2(7415):813–816.
Sebastio G, Sperandeo MP, Andria G. Lysinuric protein intolerance: reviewing concepts on a multisystem disease. Am J Med Genet C Semin Med Genet. 2011;157C(1):54–62.
Parenti G, Sebastio G, Strisciuglio P, et al. Lysinuric protein intolerance characterized by bone marrow abnormalities and severe clinical course. J Pediatr. 1995;126(2):246–251.
Simon DB, Karet FE, Hamdan JM, et al. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet. 1996;13(2):183–188.
Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet. 1996;12(1):24–30.
Blanchard A, Bockenhauer D, Bolignano D, et al. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017;91(1):24–33.
Kleta R, Bockenhauer D. Bartter syndromes and other salt-losing tubulopathies. Nephron Physiol. 2006;104(2):p73–p80.
Vargas-Poussou R, Dahan K, Kahila D, et al. Spectrum of mutations in Gitelman syndrome. J Am Soc Nephrol. 2011;22(4):693–703.
Feliubadalo L, Font M, Purroy J, et al. Non-type I cystinuria caused by mutations in SLC7A9, encoding a subunit (b0,+AT) of rBAT. Nat Genet. 1999;23(1):52–57.
Kandasamy P, Gyimesi G, Bhatt DL, et al. Solute carrier transporters: the key to unlocking the potential of substrate-specific drug delivery. Nat Rev Drug Discov. 2021;20(8):637–661.
Pizzagalli MD, Bensimon A, Superti-Furga G. A guide to plasma membrane solute carrier proteins. FEBS J. 2021;288(9):2784–2835.

Disclosure: The authors declare no conflicts of interest. No funding was received for this review.

Correspondence:drneerajmanikath@gmail.com

Word count (main text, excluding abstract and references): ~3,100 words

learningmedicine

Tuesday, February 17, 2026